Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis

Human Immunology

Volumn 60, Issue 8, 1999, Pages 677-687

  Yacyshyn, Bruce ^a   Maksymowych, Walter ^a   Bowen Yacyshyn, Mary Beth ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ABC transporters; Cyclosporine; Inflammatory bowel diseases; Multidrug resistance

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P;

ARTICLE; COLON CROHN DISEASE; DIAGNOSTIC VALUE; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

ADULT; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MIDDLE AGED; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0032776623     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00036-1     Document Type: Article

References (27)

1. Yacyshyn B.R. Activated CD19 population in ulcerative colitis lamina propria mononuclear cells. J Immunol Cell Biol. 71:1993;265.
2. Yacyshyn B.R., Pilarski L.M. Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease. GUT. 34:1993;1698.
3. Pallone F., Fais S., Squarcia O., Biancone L., Pozzilli P., Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens . GUT. 28:(6):1987;745.
4. Schreiber S., MacDermott R.P., Raedler A., Pinnau R., Bertovich M.J., Nash G.S. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology. 101:(4):1991;1020.
5. Yacyshyn B.R., Lazarovits A., Tsai V., Matejko K. Crohn's disease, ulcerative colitis and normal intestinal lymphocytes express integrins in a dissimilar pattern. Gastroenterology. 107:1994;1364.
6. Kusugami K., Youngman K.R., West G.A., Fiocchi C. Intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis and controls. Gastroenterology. 97:1989;1.
7. Faulds D., Goa K.L., Benfield P. Cyclosporine A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders . Drugs. 45:(6):1993;953.
8. Feagan B.G., McDonald J.W., Rochon J., Laupacis A., Fedorak R.N., Kinnear D., Saibil F., Gross A., Archambault A., Gillies R. Low dose Cyclosporine for the treatment of Crohn's disease The Canadian Crohn's Relapse Prevention Trial Investigators . N Engl J Med. 330:(26):1994;1846.
9. Brynskov J., Freund L., Norby Rasmussen S., Lauritsen K., Schaffalitzky de Mukadell O., Williams C.N., MacDonald A.S., Tanton R., Molina F., Campanini M.C. Final report in a placebo-controlled, double-blind, randomized, multicentre trial of Cyclosporine treatment in active Crohn's disease. Scand J Gastroenterol. 26:(7):1991;689.
10. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Gallen G., Michelassi F., Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 330:(26):1994;1841.
11. Kozarek R., Bedard C., Patterson D., Justus P., Sandford R., Greene M., Gelfand M., Bredfeldt J., Brentnall T., Putnam W. Cyclosporine use in the pre-colectomy chronic ulcerative colitis patient a community experience and its relationship to prospective and controlled trials . Am J Gastroenterol. 90:(12):1995;2093.
12. Valverde M.A., Diaz M., Sepulveda F.V., Gill D.R., Hyde S.C., Higgins C.F. Volume-regulated chlorine channels associated with the human multidrug-resistance P-glycoprotein. Nature. 355:(6363):1992;830.
13. Abraham E.H., Prat A.G., Gerweck L., Seneveratne T., Arceci R.J., Kramer R., Guidotti G., Cantiello H.F. The multidrug resistance (MDR1) gene product functions as an ATP channel. Proc Natl Acad Sci USA. 90:(1):1993;312.
14. Gill D.R., Hyde S.C., Higgins C.D., Valverde M.A., Mintenig G.M., Sepulveda F.V. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell. 71:(1):1992;23.
15. Yacyshyn B.R., Bowen-Yacyshyn M.B., Pilarski L.M. Inhibition by Rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol. 43:1996;449.
16. Pilarski L.M., Belch A.R. Circulating monoclonal B-cells expressing P-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood. 83:(13):1994;724.
17. Pilarski L.M., Paine D., McElhaney J.E., Cass C.E., Belch A.R. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes Modulation with differentiation stage and during ageing . Am J Hematol. 49:(4):1995;323.
18. Higgins C.F. ABC transporters From microorganisms to man . Ann Rev Cell Biol. 8:1992;67.
19. Goldberg H., Ling V., Wong P.Y., Skoreki K. Reduced Cyclosporine accumulation in multidrug-resistant cells. Biochem Biophys Res Commun. 152:(2):1988;552.
20. Feller N., Kuiper C.M., Lankelma J., Ruhdal J.K., Scheper R.J., Pinedo H.M., Broxterman H.J. Functional detection of MDR1/Pgp-170-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer. 72:1995;543.
21. Brandtzaeg P. Basic mechanisms of mucosal immunity A major adaptive defence system . Immunologist. 313:1995;89.
22. Neil G.A., Summers R.W., Cheyne B.A., Carpenter C., Huang W.L., Waldschmidt T.J. Analysis of T-lymphocyte subpopulations in inflammatory bowel disease by three color flow cytometry. Digest Dis Sci. 39:(9):1994;1900.
23. Muller S., Lory J., Corazza N., Griffiths G.M., Z'graggen K., Mazzucchelli L., Kappeler A., Mueller C. Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am J Pathol. 152:1998;261.
24. Fiocchi C. Inflammatory bowel disease Etiology and pathogenesis . Gastroenterology. 115:1998;182.
25. Fogler W.E., Pearson J.W., Volker K., Ariyoshi K., Watabe H., Riggs C.W., Wiltrout R.H., Longo D.L. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. JNCI. 87:1995;94.
26. Bailly J.D., Pourquier P., Jaffrezou J.P., Duchayne E., Cassar G., Bordier C., Laurent G. Effect of 5637 conditioned medium and recombinant cytokines on P-glycoprotein expression in a human GM-CSF dependent leukemic myeloid cell line. Leukemia. 9:(10):1995;1718.
27. Stein U., Walther W., Laurencot C.M., Scheffer G.L., Scheper R.J., Shoemaker R.H. Tumor necrosis factor alpha and expression of the multidrug resistance associated genes LRP and MRP. JNCI. 89:1997;807.